LLY stock: buy or sell?
September 20th, 2019
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products.
Should I buy LLY stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Check the only buy setup that matches with Eli Lilly and stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||Yes|
|100d MA crossing up 200d MA||No|
Is Eli Lilly and stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we gathered 9 ratings published for LLY stock in the last month. The general sentiment of these ratings is bullish for LLY stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-10||Bank of America||n/a||Neutral|
|2019-5-28||Goldman Sachs Group||n/a||Buy|
|2019-3-22||Credit Suisse Group||n/a||Hold|
|2019-3-12||JPMorgan Chase & Co.||Overweight||Overweight|
LLY stock analysis
Eli Lilly and shares broke up the SMA line of 200 days today and closed at $116.16.
Eli Lilly and broke up the SMA line of 200 days today and closed at $116.16. LLY broke out again over $112.42 after a 2.86% correction started on Sep/12.
Eli Lilly and shares crossed up the SMA line of 200d, closing at $116.16.
If you observe the weekly chart, price finally broke over the resistance at $115.49 and continued climbing. Far behind is the all-time high Eli Lilly and hit late March and since then the price is -11.10% below that top.
LLY stock price history
LLY stock historical price chart
LLY stock reached all-time highs on March with a price of $130.66.
LLY stock price target is $119.30How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 6 price predictions for Eli Lilly and stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-10||Bank of America||Reiterates||$118.00||$120.00||1.7%|
|2019-5-28||Goldman Sachs Group||Initiates||n/a||$135.00||-|
|2019-3-22||Credit Suisse Group||Set Price Target||n/a||$121.00||-|
|2019-3-12||JPMorgan Chase & Co.||Initiates||n/a||$140.00||-|
|2019-2-8||UBS Group||Lowers Target||$107.53||$100.00||-7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter posting its last earnings report on April, Eli Lilly and . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a great growth of 7.36% to $24,555.70 M dollars. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) skyrocketed a 14.05% to 13.16%. To have an updated picture of the financial situation of Eli Lilly and, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Eli Lilly and TTM sales up to March 2019 were $23,947.90 and income was $6,256.20 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Eli Lilly and business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, decreased an unpleasant -2.48%. Regarding profit margin, Eli Lilly and rocketed 12.96% to 13.16%
|2013||$23,110 M||-||$4,680 M20.3%||-|
|2014||$19,616 M||-15.12%||$2,391 M12.2%||-48.92%|
|2015||$19,959 M||1.75%||$2,408 M12.1%||0.75%|
|2016||$21,222 M||6.33%||$2,738 M12.9%||13.67%|
|2017||$22,871 M||7.77%||$-204.10 M-0.9%||-107.46%|
|2018||$24,556 M||7.36%||$3,232 M13.2%||-1,683.54%|
|TTM||$23,948 M||-2.48%||$6,256 M26.1%||93.57%|
Quarterly financial resultsEli Lilly and reported $5,092.20 M in revenues for 2019-Q1, a -20.91% less compared to previous quarter. Reported quarter income marked $4,241.60 M with a profit margin of 83.30%. Profit margin boosted a 65.82% compared to previous quarter when profit margin was 17.47%. When comparing turnover to same quarter last year, Eli Lilly and sales marked a horrible decrease and plummed a -10.66%.
|2017-Q2||$5,820 M||-||$1,010 M17.4%||-|
|2017-Q3||$5,658 M||-2.78%||$556 M9.8%||-44.99%|
|2017-Q4||$6,161 M||8.88%||$-1,657 M-26.9%||-398.22%|
|2018-Q1||$5,700 M||-7.48%||$1,217 M21.4%||-173.47%|
|2018-Q2||$6,355 M||11.49%||$-260 M-4.1%||-121.35%|
|2018-Q3||$6,062 M||-4.62%||$1,150 M19.0%||-542.29%|
|2018-Q4||$6,439 M||6.21%||$1,125 M17.5%||-2.13%|
|2019-Q1||$5,092 M||-20.91%||$4,242 M83.3%||277.03%|
Eli Lilly and ownershipWhen you are planning to buy a company, it's always worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Eli Lilly and, 0.12% of all outstanding shares are owned by its staff.
Bearish positions for LLY stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$112.1 B||$106.1 B||$118.1 B||$82.9 B||$103.7 B|
|Total shares||965.4 M||1,480.0 M||599.7 M||1,640.0 M||2,490.0 M|
|Float shares||796.2 M||1,480.0 M||598.3 M||1,630.0 M||2,450.0 M|
|- Institutional holdings (%)||81.5%||71.9%||81.9%||75.0%||11.0%|
|- Insider holdings (%)||0.1%||0.1%||0.2%||0.1%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$114.47 - $117.23|
|Average true range||$2.26|
|50d mov avg||$110.68|
|100d mov avg||$112.47|
|200d mov avg||$115.45|
Eli Lilly and performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Eli Lilly and performance to AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, , Merck, Novartis, Pfizer and :
|LLYEli Lilly and||1.14%||-8.44%||11.63%|
Eli Lilly and competitorsWe chose a few stocks to conform a list of Eli Lilly and competitors to watch if you are interested in investing in LLY:
- AbbVie (ABBV)
- Amgen (AMGN)
- Bristol-Myers Squibb (BMY)
- GlaxoSmithKline (GSK)
- Merck (MRK)
- Novartis (NVS)
- Pfizer (PFE)
Latest LLY stock news
- Seeking AlphaEli Lilly And Baricitinib In PBC: What's The Story?July 10, 2019
- InvestorPlace3 Big Stock Charts for Wednesday: Juniper Networks, Eli Lilly and Hormel FoodsMay 29, 2019
- InvestorPlace3 Big Stock Charts for Wednesday: FMC, Eli Lilly and Hewlett Packard EnterpriseSeptember 5, 2018
- Seeking AlphaNeuroscience In Big Pharma: Eli LillyAugust 20, 2018
- Seeking AlphaDiabetes And Upcoming REWIND Data Key Topics Of Debate For Eli LillyAugust 13, 2018